The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh, at the Polymers in Medicine and Biology Workshop, Napa (CA – USA) on Wednesday 30 November.
The favourable outcomes included rapid infiltration of tissue cells, formation of new blood vessels, low levels of calcification and a dominant presence of anti-inflammatory macrophage phenotype (M2-like) compared to materials currently used for prosthetic heart valves and vascular grafts.
“This study helped deepening the understanding of the host response mechanisms that support appropriate tissue restoration for cardiovascular use,”
explained Martijn Cox, Xeltis CTO.
The Polymers in Medicine and Biology Workshop (POLY) is organised by the Division of Polymer Chemistry of the American Chemical Society. It started in 1992 in view of the need to use polymers in medicine and biology, as a scientifically and commercially important area that has attracted a large number of interdisciplinary scientists and engineers.
